Imatinib mesylate in conjunction with allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome positive leukemias: Report of 4 cases

Tohoku Journal of Experimental Medicine

Volumn 204, Issue 1, 2004, Pages 79-84

  Yamada, Minami ^a   Miyamura, Koichi ^a   Fujiwara, Tohru ^a   Yokoyama, Hisayuki ^a   Tomiya, Yasuo ^a   Ishizawa, Kenichi ^a   Harigae, Hideo ^a   Kameoka, Junichi ^a   Sasaki, Takeshi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Imatinib mesylate; Philadelphia chromosome positive leukemia; STI571

Indexed keywords

AMPHOTERICIN B; CYCLOSPORIN A; CYTOCHROME P450 3A4; IMATINIB; MIZORIBINE; PREDNISOLONE; STEROID; TACROLIMUS;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA REMISSION; LUNG ASPERGILLOSIS; MALE; PHILADELPHIA CHROMOSOME POSITIVE CELL; STATISTICAL SIGNIFICANCE;

ADULT; ANTINEOPLASTIC AGENTS; CYCLOSPORINE; ENZYME INHIBITORS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 5044232258     PISSN: 00408727     EISSN: None     Source Type: Journal    
DOI: 10.1620/tjem.204.79     Document Type: Article

References (13)

1. Hesselink, D.A., van Schaik, R.H.N., van der Heiden, I.P., van der Werf, M., Smak Gregoor, P.J.H., Lindemans, J., Weimar, W. & van Gelder, T. (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther., 74, 245-254.
2. Kantarjian, H.M., O'Brien, S., Cortes, J.E., Giralt, S.A., Rios, M.B., Shan, J., Giles, F.J., Thomas, D.A., Faderi, S., Lima, D.M., Garcia-Manero, G., Champlin, R., Arlinghaus, R. & Talpaz, M. (2002) Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood, 100, 1590-1595.
3. Kantarjian, H., Talpaz, M., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Giles, F., Rios, M.B., Shan, J., Letvak, L., Thomas, D., Faderi, S., Ferrajoli, A. & Cortes, J. (2004) High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood, 103, 2873-2878.
4. Mensink, E., van de Locht, A., Schattenberg, A., Linders, E., Schaap, N., Geurts van Kessel, A. & De Witte, T. (1998) Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br. J. Hematol., 102, 768-774
5. Miyamura, K., Tanimoto, M., Morishima, Y., Horibe, K., Yamamoto, K., Akatsuka, M., Kodera, Y., Kojima, S., Matsuyama, K., Hirabayashi, N., Yazaki, M., Imai, K., Onozawa, Y., Kanamaru, A., Mizutani, S. & Saito, H. (1992) Detection of Philadelohia chrosome-positive acute lymphoblastic leukemia by polymerase chain reaction: Possible eradication of minimal residual disease by marrow transplantation. Blood, 79, 1366-1370.
6. Neumann, F., Herold, C., Hildebrandt, B., Kobbe, G., Aivado, M., Rong, A., Free, M., Rossig, R., Fenk, R., Schneider, P., Gattermann, N., Royer-Porora, B., Haas, R. & Kronenwett, R. (2003) Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur. J. Haematol., 70, 1-10.
7. O'Brien, S.G., Meinhardt, P., Bond, E., Beck, J., Peng, B., Dutreix, C., Mehring, G., Milosavljev, S., Huber, C., Capdeville, R. & Fischer, T. (2003) Effects of imatinib (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia. Br. J. Cancer., 89, 1855-1859.
8. Olavarria, E., Craddock, C., Dazzi, F., Marin, D., Marktel, S., Apperley, J.F. & Goldman, J.M. (2002) Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood, 99, 3861-3862.
9. Olavarria, E., Ottmann, O.G., Deininger, M., Clark, R.E., Bandini, G., Byrne, J., Lipton, J., Vitek, A., Michallet, M., Siegert, W., Ullmann, A., Wassmann, B., Niederwieser, D. & Fischer, T. (2003) Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia, 17, 1707-1712.
10. Ottmann, O.G., Druker, B.J., Sawyers, C.L., Goldman, J.M., Reiffers, J., Silver, R.T., Tura, S., Fischer, T., Deininger, M.W., Schiffer, C.A., Baccarani, M., Gratwohl, A., Hochhaus, A., Hoelzer, D., Fernandes-Reese, S., Gathmann, I., Capdeville, R. & O'Brien, S.G. (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood, 100, 1965-1971.
11. Scheuring, U.J., Pfeifer, H., Wassmann, B., Bruck, P., Gehrke, B., Petershofen, E.K., Gschaidmeier, H., Hoelzer, D. & Ottmann, O.G. (2003) Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) during imatinib treatment. Leukemia, 17, 1700-1706.
12. Shimoni, A., Kroger, N., Zander, A.R., Rowe, J.M., Hardan, I., Avigdor, A., Yeshurun, M., Ben-Bassat, I. & Nagler, A. (2003) Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lympohocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia, 17, 290-297.
13. Wassmann, B., Pfeifer, H., Scheuring, U., Klein, S.A., Gokbuget, N., Martin, H., Hoelzer, D. & Ottmann, O.G. (2002) Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia, 16, 2358-2365.